First Drug In A New Class Treats Type 2 Diabetes

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 113, Nº. 7, 2013, págs. 21-22
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * Canagliflozin (Invokana) is the first drug in a new class approved for the treatment of type 2 diabetes.

    * It promotes the renal excretion of glucose and, consequently, diuresis; as a result, patients can develop hypovolemia and hypotension.

    * Canagliflozin should be avoided in patients with serious renal insufficiency.